Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Murthy RK, et al. N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825569 Clinical Trial.
Outcomes of children exposed in utero to chemotherapy for breast cancer.
Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, Rimes SA, Hortobagyi GN, Valero V, Litton JK. Murthy RK, et al. Breast Cancer Res. 2014 Dec 30;16(6):500. doi: 10.1186/s13058-014-0500-0. Breast Cancer Res. 2014. PMID: 25547133 Free PMC article.
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).
Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, Chavira R, Guthrie K, Barrett E, Chia SK. Moulder SL, et al. Among authors: murthy rk. Clin Cancer Res. 2017 Jul 15;23(14):3529-3536. doi: 10.1158/1078-0432.CCR-16-1496. Epub 2017 Jan 4. Clin Cancer Res. 2017. PMID: 28053022 Clinical Trial.
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. Yam C, et al. Among authors: murthy rk. Invest New Drugs. 2018 Apr;36(2):299-306. doi: 10.1007/s10637-018-0564-2. Epub 2018 Jan 27. Invest New Drugs. 2018. PMID: 29374384 Clinical Trial.
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Basho RK, et al. Among authors: murthy rk. Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23. Oncologist. 2018. PMID: 30139837 Free PMC article.
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.
Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. Yam C, et al. Among authors: murthy rk. Invest New Drugs. 2018 Dec;36(6):1103-1109. doi: 10.1007/s10637-018-0672-z. Epub 2018 Oct 11. Invest New Drugs. 2018. PMID: 30311036 Clinical Trial.
135 results